Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.41 |
| ▸ | CA2 | P00918 | 11/20 | 0.41 |
| ▸ | CA9 | Q16790 | 9/20 | 0.41 |
| ▸ | CA12 | O43570 | 6/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA6 | P23280 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6111191 | 0.82 | CA2 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL3853245 | 0.82 | CA1 (0.46) | CA1CA2CA9CA12CA4 | |
| SCHEMBL6700698 | 0.80 | EDNRA (0.39) | CA1CA2CA9CA12STAT3 | |
| SCHEMBL48885 | 0.78 | CA2 (0.52) | CA1CA2CA9CA12CA4 | |
| SCHEMBL9806251 | 0.78 | PDCD1 (0.47) | PTGS2 | |
| SCHEMBL2896796 | 0.77 | LRRK2 (0.51) | CA1CA2CA9CA12CA4 | |
| SCHEMBL6111776 | 0.77 | SCN9A (0.42) | CA1CA2CA9CA12CA4 | |
| SCHEMBL2170005 | 0.77 | CA2 (0.42) | CA1CA2CA9CA12CA4 | |
| Hydrochloric Acid SCHEMBL6399557 | 0.76 | CA2 (0.50) | CA1CA2CA9CA12CA4 | |
| Methane SCHEMBL27503773 | 0.76 | CA2 (0.50) | CA1CA2CA9CA12CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108025001-A | Gamma secretase modulators for the treatment of immune system dysfunction | 安可初克公司 | 2018-05-11 | — | — | CN | claimed |
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2018-07-17 | — | — | US | disclosed |
| CN-108025001-A | Gamma secretase modulators for the treatment of immune system dysfunction | 安可初克公司 | 2018-05-11 | — | — | CN | disclosed |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. (US) | 2017-03-16 | — | — | US | disclosed |
| US-9518052-B2 | Pyrazolopyridines and pyrazolopyrimidines | PFIZER INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | PFIZER INC. | 2015-11-19 | — | — | US | disclosed |
| CN-104869987-A | Methods and compositions for regenerating hair cells and/or supporting cells | MASSACHUSETTS EYE & EAR INFIRM | 2015-08-26 | — | — | CN | disclosed |
| US-6967196-B1 | Sulfonamide compounds and uses thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10022376-B2 | Pyrazolopyridines and pyrazolopyrimidines | CBR3, HRH4, REN | CA1 2503/4885CA2 358/4885CA9 1800/4885 |
| US-20150329542-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | CA1 2724/4885CA2 361/4885CA9 1782/4885 |
| US-20170071946-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIMIDINES | HRH2, HRH4, HRH1 | CA1 2724/4885CA2 361/4885CA9 1782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.